fluoride1337
Gold
- Joined
- Jul 26, 2023
- Posts
- 970
- Reputation
- 1,227
"GT20029 is a topical gel that works as an androgen receptor degrader. This medication is specifically known as a proteolysis-targeting chimera (“PROTAC”) drug. It’s actually the first topical PROTAC drug to ever go through clinical trials.
In a press release, Kintor’s founder, chairman, and CEO, Dr. Tong Youzhi, said that the “major obstacle of PROTAC drugs is oral absorption due to the large molecular weight. Therefore, we developed a topical AR degrader first based on the PROTAC platform."
hairscience.org
"The 0.5% QD group saw an increase of 16.80 hairs/cm², and the 1% BIW group saw an increase of 11.94 hairs/cm², both surpassing placebo results with statistical significance."
QD = Once Daily, BIW = Twice weekly, so it's showing promising results even when only applied biweekly.
www.clinicaltrialsarena.com
The compound passed phase I and II clinical trials in China, and is currently being tested in the US.
The only bad news is it would most likely take several more years before it is officially released to the public (grey market manufacturers will make it at least
), and the company who made it, Kintor Pharmaceuticals, also had a promising antiandrogen called pyrilutamide (KX-826) that failed when it underwent phase III trials in the US
thebambooworks.com
In a press release, Kintor’s founder, chairman, and CEO, Dr. Tong Youzhi, said that the “major obstacle of PROTAC drugs is oral absorption due to the large molecular weight. Therefore, we developed a topical AR degrader first based on the PROTAC platform."
Kintor Advances With GT20029 Clinical Trials for Hair Loss - HairScience
GT20029 is a new hair loss treatment being developed by Kintor Pharma. It's a topical androgen receptor degrader that can damage androgen receptor proteins.
hairscience.org
"The 0.5% QD group saw an increase of 16.80 hairs/cm², and the 1% BIW group saw an increase of 11.94 hairs/cm², both surpassing placebo results with statistical significance."
QD = Once Daily, BIW = Twice weekly, so it's showing promising results even when only applied biweekly.
Kintor Pharma's GT20029 Phase II trial meets primary endpoint
Kintor Pharma has announced that its GT20029 China Phase II trial in China has met the primary endpoint, showing significant results in treating male AGA.
www.clinicaltrialsarena.com
The compound passed phase I and II clinical trials in China, and is currently being tested in the US.
The only bad news is it would most likely take several more years before it is officially released to the public (grey market manufacturers will make it at least
), and the company who made it, Kintor Pharmaceuticals, also had a promising antiandrogen called pyrilutamide (KX-826) that failed when it underwent phase III trials in the US
Kintor Pharma eyes regeneration with over-the-counter cosmetic treatments - Bamboo Works - Where China Stocks meet global investors
Suzhou-based Kintor will commercialize its hair-loss product despite disappointing clinical testing results
thebambooworks.com
